AstraZeneca PLC
AZN64.900USD
-0.890-1.35%
Close 04/08, 16:00（ET）Quotes delayed by 15 min
201.26BMarket Cap
28.61P/E TTM
More Details of AstraZeneca PLC Company
AstraZeneca PLC is a science-led biopharmaceutical company. It discovers, develops, and commercializes prescription medicines in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal and metabolism, respiratory and immunology and vaccines and immune therapies. Its key marketed oncology products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Zoladex, Faslodex and others. Its rare diseases products include Soliris, Ultomiris, Strensiq and Kanuma. Its biopharmaceuticals products include Farxiga, Crestor, Breztri and others. Its investigational vaccine candidate IVX-A12, which targets both respiratory syncytial virus and human metapneumovirus. Its oncology candidate includes FPI-2265 targeting prostate specific membrane antigen for metastatic castration resistant prostate cancer, which is in a Phase II trial. It also discovers, develops, and manufactures T-cell receptor therapies. Its Eneboparatide is an investigational therapeutic peptide.
Company Info
Company codeAZN
Company nameAstraZeneca PLC
IPO dateSep 21, 2007
Founded at1992
CEOMr. Marc Dunoyer
Number of employees94300
Security typeOrdinary Share
Fiscal year-endSep 21
Address1 Francis Crick Avenue
CityCAMBRIDGE
Stock exchangeLondon Stock Exchange
CountryUnited Kingdom
Postal codeCB2 0AA
Phone442073045000
Websitehttps://www.astrazeneca.com/
Company codeAZN
IPO dateSep 21, 2007
Founded at1992
Company Executives
Name
Name/Position
Position
Shareholding
Change
Ms. Susan Galbraith
Ms. Susan Galbraith
Executive Vice President - Oncology and Research and Development
Executive Vice President - Oncology and Research and Development
--
--
Mr. Marc Dunoyer
Mr. Marc Dunoyer
Chief Executive Officer - Alexion, Chief Strategy Officer - AstraZeneca
Chief Executive Officer - Alexion, Chief Strategy Officer - AstraZeneca
--
--
Mr. David (Dave) Fredrickson
Mr. David (Dave) Fredrickson
Executive Vice President - Oncology Business Unit
Executive Vice President - Oncology Business Unit
--
--
Mr. Pascal Soriot
Mr. Pascal Soriot
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Mr. Philip Broadley
Mr. Philip Broadley
Senior Non-Executive Independent Director
Senior Non-Executive Independent Director
--
--
Dr. Ruud Dobber, Ph.D.
Dr. Ruud Dobber, Ph.D.
Executive Vice President - BioPharmaceuticals Business Unit
Executive Vice President - BioPharmaceuticals Business Unit
--
--
Ms. Deborah Disanzo Eldracher
Ms. Deborah Disanzo Eldracher
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Diana Layfield
Ms. Diana Layfield
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Rene Haas
Mr. Rene Haas
Non-Executive Director
Non-Executive Director
--
--
Mr. Michel Demare
Mr. Michel Demare
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Ms. Susan Galbraith
Ms. Susan Galbraith
Executive Vice President - Oncology and Research and Development
Executive Vice President - Oncology and Research and Development
--
--
Mr. Marc Dunoyer
Mr. Marc Dunoyer
Chief Executive Officer - Alexion, Chief Strategy Officer - AstraZeneca
Chief Executive Officer - Alexion, Chief Strategy Officer - AstraZeneca
--
--
Mr. David (Dave) Fredrickson
Mr. David (Dave) Fredrickson
Executive Vice President - Oncology Business Unit
Executive Vice President - Oncology Business Unit
--
--
Mr. Pascal Soriot
Mr. Pascal Soriot
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Mr. Philip Broadley
Mr. Philip Broadley
Senior Non-Executive Independent Director
Senior Non-Executive Independent Director
--
--
Dr. Ruud Dobber, Ph.D.
Dr. Ruud Dobber, Ph.D.
Executive Vice President - BioPharmaceuticals Business Unit
Executive Vice President - BioPharmaceuticals Business Unit
--
--
Revenue Breakdown
Currency: USDUpdate time: Sun, Apr 6
Currency: USDUpdate time: Sun, Apr 6
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Farxiga
7.66B
15.03%
Tagrisso
6.58B
12.92%
Imfinzi
4.72B
9.26%
Ultomiris
3.92B
7.70%
Calquenc
3.13B
6.14%
Other
24.93B
48.95%
By RegionUSD
Name
Revenue
Proportion
United States
21.81B
42.81%
China
6.42B
12.60%
United Kingdom
4.74B
9.31%
Other European Countries
3.66B
7.19%
Japan
3.45B
6.78%
Other
10.86B
21.32%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Farxiga
7.66B
15.03%
Tagrisso
6.58B
12.92%
Imfinzi
4.72B
9.26%
Ultomiris
3.92B
7.70%
Calquenc
3.13B
6.14%
Other
24.93B
48.95%
Shareholder
Update time: Fri, Feb 21
Update time: Fri, Feb 21
Shareholder Statistics
Type
Shareholder Statistics
Shareholder
Proportion
PRIMECAP Management Company
1.32%
Capital International Investors
1.21%
Wellington Management Company, LLP
1.19%
T. Rowe Price Associates, Inc.
1.09%
T. Rowe Price International Ltd
0.86%
Other
94.33%
Shareholder Statistics
Shareholder
Proportion
PRIMECAP Management Company
1.32%
Capital International Investors
1.21%
Wellington Management Company, LLP
1.19%
T. Rowe Price Associates, Inc.
1.09%
T. Rowe Price International Ltd
0.86%
Other
94.33%
Type
Shareholder
Proportion
Investment Advisor
9.47%
Investment Advisor/Hedge Fund
5.99%
Hedge Fund
0.95%
Research Firm
0.89%
Bank and Trust
0.14%
Pension Fund
0.04%
Venture Capital
0.02%
Family Office
0.02%
Family Office
0.02%
Other
82.46%
Institutional Shareholding
Update time: Sun, Jan 19
Update time: Sun, Jan 19
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q1
1957
546.41M
17.61%
+3.36M
2024Q4
1985
546.17M
17.61%
+11.21M
2024Q3
1920
519.95M
16.76%
-17.37M
2024Q2
1910
530.80M
17.12%
-10.51M
2024Q1
1865
523.00M
16.86%
-21.20M
2023Q4
1838
520.78M
16.79%
-27.28M
2023Q3
1815
530.17M
17.10%
-14.80M
2023Q2
1812
525.36M
16.94%
-28.74M
2023Q1
1803
534.31M
17.23%
-35.06M
2022Q4
1806
550.27M
17.75%
-33.14M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
PRIMECAP Management Company
41.02M
1.32%
-960.52K
-2.29%
Dec 31, 2024
Capital International Investors
37.51M
1.21%
+686.01K
+1.86%
Dec 31, 2024
Wellington Management Company, LLP
37.04M
1.19%
-208.20K
-0.56%
Dec 31, 2024
T. Rowe Price Associates, Inc.
33.74M
1.09%
-3.07M
-8.34%
Dec 31, 2024
T. Rowe Price International Ltd
26.61M
0.86%
+530.22K
+2.03%
Dec 31, 2024
Fidelity Management & Research Company LLC
18.15M
0.59%
-1.10M
-5.70%
Dec 31, 2024
Managed Account Advisors LLC
16.43M
0.53%
-1.13M
-6.44%
Dec 31, 2024
Jennison Associates LLC
15.43M
0.5%
+466.42K
+3.12%
Dec 31, 2024
Sanders Capital, LLC
15.19M
0.49%
+212.30K
+1.42%
Dec 31, 2024
Invesco Capital Management (QQQ Trust)
12.04M
0.39%
+161.77K
+1.36%
Feb 28, 2025
View more
Related ETFs
Update time: Sat, Apr 5
Update time: Sat, Apr 5
Name
Proportion
First Trust WCM International Equity ETF
6.02%
Amplify Weight Loss Drug & Treatment ETF
5.95%
Parnassus Value Select ETF
5.6%
VanEck Pharmaceutical ETF
5.09%
Roundhill GLP-1 & Weight Loss ETF
4.88%
ProShares Ultra Nasdaq Biotechnology
4.27%
Invesco Nasdaq Biotechnology ETF
4.25%
Invesco QQQ Low Volatility ETF
4.19%
PGIM Jennison Focused Value ETF
3.39%
Global X Aging Population ETF
2.87%
View more
First Trust WCM International Equity ETF
Proportion6.02%
Amplify Weight Loss Drug & Treatment ETF
Proportion5.95%
Parnassus Value Select ETF
Proportion5.6%
VanEck Pharmaceutical ETF
Proportion5.09%
Roundhill GLP-1 & Weight Loss ETF
Proportion4.88%
ProShares Ultra Nasdaq Biotechnology
Proportion4.27%
Invesco Nasdaq Biotechnology ETF
Proportion4.25%
Invesco QQQ Low Volatility ETF
Proportion4.19%
PGIM Jennison Focused Value ETF
Proportion3.39%
Global X Aging Population ETF
Proportion2.87%
Dividend
A total of
20.90B
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
Feb 06, 2025
AZN.NB Interim Cash Dividend of gross USD 1.05 paid on Mar 24, 2025 going ex on Feb 21, 2025
Feb 21, 2025
Mar 24, 2025
Feb 21, 2025
Jul 25, 2024
AZN.NB Final Cash Dividend of gross USD 0.5 paid on Sep 09, 2024 going ex on Aug 09, 2024
Aug 09, 2024
Sep 09, 2024
Aug 09, 2024
Feb 08, 2024
AZN.NB Interim Cash Dividend of gross USD 0.985 paid on Mar 25, 2024 going ex on Feb 22, 2024
Feb 23, 2024
Mar 25, 2024
Feb 22, 2024
Jul 28, 2023
AZN.NB Final Cash Dividend of gross USD 0.465 paid on Sep 11, 2023 going ex on Aug 10, 2023
Aug 11, 2023
Sep 11, 2023
Aug 10, 2023
Feb 10, 2023
AZN.NB Interim Cash Dividend of gross USD 0.985 paid on Mar 27, 2023 going ex on Feb 23, 2023
Feb 24, 2023
Mar 27, 2023
Feb 23, 2023
Aug 01, 2022
AZN.NB Final Cash Dividend of gross USD 0.465 paid on Sep 12, 2022 going ex on Aug 11, 2022
Aug 12, 2022
Sep 12, 2022
Aug 11, 2022
Feb 10, 2022
AZN.NB Interim Cash Dividend of gross USD 0.985 paid on Mar 28, 2022 going ex on Feb 24, 2022
Feb 25, 2022
Mar 28, 2022
Feb 24, 2022
Aug 02, 2021
AZN.NB Final Cash Dividend of gross USD 0.45 paid on Sep 13, 2021 going ex on Aug 12, 2021
Aug 13, 2021
Sep 13, 2021
Aug 12, 2021
Feb 11, 2021
AZN.NB Interim Cash Dividend of gross USD 0.95 paid on Mar 29, 2021 going ex on Feb 25, 2021
Feb 26, 2021
Mar 29, 2021
Feb 25, 2021
Jul 30, 2020
AZN.NB Final Cash Dividend of gross USD 0.45 paid on Sep 14, 2020 going ex on Aug 13, 2020
Aug 14, 2020
Sep 14, 2020
Aug 13, 2020
View more
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data